Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 7 - Net Income (Loss) Per Share

Note 7 - Net Income (Loss) Per Share

6 Months Ended

Jun. 30, 2026

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 7 – Net Income (Loss) Per Share

Basic and diluted net income (loss) per common share was calculated as follows:

	*Three Months Ended June 30,*						*Six Months Ended June 30,*
(in thousands, except for net income (loss) per share)	*2026*			*2025*			*2026*			*2025*
Numerator:
Net income (loss)	$	(5,313	)	$	(2,454	)	$	(9,206	)	$	(5,078	)

Denominator:
Weighted-average common shares outstanding, basic and diluted⁽¹⁾		8,542			6,998			8,539			6,993

Net income (loss) per common share, basic and diluted	$	(0.62	)	$	(0.35	)	$	(1.08	)	$	(0.73	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share
Stock options to purchase common stock		678			627			678			627
Unvested restricted stock units		145			128			145			128

(1)

Pre-funded warrants outstanding during the three and six months ended June 30, 2026 and 2025, are exercisable at a nominal price and are considered, in substance, equivalent to outstanding common stock. Accordingly, such pre-funded warrants have been included in the calculation of weighted-average shares of common stock outstanding for purposes of basic and diluted net income (loss) per share.